Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Dysregulated Wnt signaling is associated with the pathogenesis of cancers, fibrosis, and vascular diseases. Inhibition of Wnt signaling has shown efficacy in various pre-clinical models of these disorders. One of the key challenges in developing targeted anti-cancer drugs is to balance efficacy with on-target toxicity. Given the crucial role Wnts play in the differentiation of osteoblasts and osteoclasts, acute inhibition of Wnt signaling is likely to affect bone homeostasis. In this study, we evaluated the skeletal effect of small molecule inhibitor of an o-acyl transferase porcupine (PORCN) that prevents Wnt signaling by blocking the secretion of all Wnts. Micro-computed tomography and histomorphometric evaluation revealed that the bones of mice treated with two structurally distinct PORCN inhibitors LGK974 and ETC-1922159 (ETC-159) had loss-of-bone volume and density within 4 weeks of exposure. This decreased bone mass was associated with a significant increase in adipocytes within the bone marrow. Notably, simultaneous administration of a clinically approved anti-resorptive, alendronate, a member of the bisphosphonate family, mitigated loss-of-bone mass seen upon ETC-159 treatment by regulating activity of osteoclasts and blocking accumulation of bone marrow adipocytes. Our results support the addition of bone protective agents when treating patients with PORCN inhibitors. Mitigation of bone toxicity can extend the therapeutic utility of Wnt pathway inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Day, T. F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.03.016 · Cited by 1,616
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Sequential roles of Hedgehog and Wnt signaling in osteoblast development
Hu, H., Hilton, M. J., Tu, X., Yu, K., Ornitz, D. M., & Long, F. (2005) · Development · doi:10.1242/dev.01564 · Cited by 682
Essential role of β-catenin in postnatal bone acquisition.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M.-C., Bouxsein, M. L., Deng, L., Clemens, T. L., & Williams, B. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501900200 · Cited by 584 · cited 2×
“and/or osteocytes causes severe osteopenia associated with increased osteoclastogenesis.(20) These findings demonstrate that in adults Wnt/β-catenin signaling promotes the ability of differentiated osteoblasts to inhibit osteoclast differentiation.”
BackgroundSelf-citationSecretion of Wnt Ligands Requires Evi, a Conserved Transmembrane Protein
Bartscherer, K., Pelte, N., Ingelfinger, D., & Boutros, M. (2006) · Cell · doi:10.1016/j.cell.2006.04.009 · Cited by 580
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Results showed that there were no significant differences in several estimated outcomes of bone between treated daily and treated every other day.(280) By the way, ETC131, a similar compound of ETC159, is only used for in vitro assays as a result of its inferior oral bioavailability.”
BackgroundInfluentialMutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
WNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257
Metadata
- Authors
- Madan, B., McDonald, M. J., Foxa, G. E., Diegel, C. R., Williams, B. O., & Virshup, D. M.
- Venue
- Bone Research
- Published
- 2018-05-25
- Volume
- 6
- Issue
- 1
- Pages
- 17-17
- ISSN
- 2095-4700 (ISSN-L)
- 2095-6231
- OpenAlex
- W2803586435
- Cited by
- 99
- References
- 9
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. https://app.cochat.ai/papers/10.1038/s41413-018-0017-8
- The paper
- Madan, B., McDonald, M. J., Foxa, G. E., Diegel, C. R., Williams, B. O., & Virshup, D. M. (2018). Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Research. https://doi.org/10.1038/s41413-018-0017-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.